179 related articles for article (PubMed ID: 31774932)
1. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
[TBL] [Abstract][Full Text] [Related]
2. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy.
Chen IP; Ariizumi S; Nakano M; Yamamoto M
J Gastroenterol; 2014 Jan; 49(1):117-25. PubMed ID: 23532638
[TBL] [Abstract][Full Text] [Related]
3. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Gomaa SH; Abaza MM; Elattar HA; Amin GA; Elshahawy DM
Arab J Gastroenterol; 2020 Dec; 21(4):224-232. PubMed ID: 32891543
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.
Ozkan H; Erdal H; Koçak E; Tutkak H; Karaeren Z; Yakut M; Köklü S
J Clin Lab Anal; 2011; 25(5):350-3. PubMed ID: 21919070
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
6. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
9. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.
Mu H; Lin KX; Zhao H; Xing S; Li C; Liu F; Lu HZ; Zhang Z; Sun YL; Yan XY; Cai JQ; Zhao XH
World J Gastroenterol; 2014 May; 20(19):5826-38. PubMed ID: 24914343
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.
Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H; Alavian SM; Lankarani KB; Farrokh P; Randel Nyengaard J
Eur J Histochem; 2018 Jan; 62(1):2859. PubMed ID: 29569872
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.
Wang YL; Zhu ZJ; Teng DH; Yao Z; Gao W; Shen ZY
World J Gastroenterol; 2012 May; 18(19):2408-14. PubMed ID: 22654434
[TBL] [Abstract][Full Text] [Related]
12. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
[TBL] [Abstract][Full Text] [Related]
13. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
14. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
16. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
19. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
